share_log

Canaccord Genuity Maintains Buy on Regulus Therapeutics, Lowers Price Target to $11

Canaccord Genuity Maintains Buy on Regulus Therapeutics, Lowers Price Target to $11

Canaccord Genuity维持对Regulus Therapeutics的买入,将目标股价下调至11美元
Benzinga ·  03/19 08:12

Canaccord Genuity analyst Whitney Ijem maintains Regulus Therapeutics (NASDAQ:RGLS) with a Buy and lowers the price target from $12 to $11.

Canaccord Genuity分析师惠特尼·伊杰姆维持Regulus Therapeutics(纳斯达克股票代码:RGLS)的买入并将目标股价从12美元下调至11美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发